AMY HUMMEL: Open Payments
NPI 1821291758 · AURORA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,239 in 67 payments from 17 companies in 2025. Trend: 2023 $582 · 2024 $1,096 · 2025 $1,239
Food & beverage: $1,239
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $461 |
| PFIZER INC. | 7 | $117 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $112 |
| Novo Nordisk Inc | 6 | $95 |
| Lilly USA, LLC | 4 | $77 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $68 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| Astellas Pharma US Inc | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $34 |
Products named: VRAYLAR, QULIPTA, CAPLYTA, Ozempic, Kerendia, UBRELVY, NURTEC ODT, REXULTI.
Industry payments across IN — which companies pay providers there.
